blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2502936

EP2502936 - HIGHLY-FUNCTIONAL MUTANT OF HUMANIZED ANTI-EGFR ANTIBODY VARIABLE REGION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.11.2016
Database last updated on 13.07.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Tohoku University
1-1 Katahira 2-chome Aoba-ku Sendai-shi
Miyagi 980-8577 / JP
[2012/39]
Inventor(s)01 / KUMAGAI, Izumi
c/o TOHOKU UNIVERSITY
1-1 Katahira 2-chome
Aoba-ku
Sendai-shi Miyagi 980-8577 / JP
02 / NAKANISHI, Takeshi
c/o TOHOKU UNIVERSITY
1-1 Katahira 2-chome
Aoba-ku
Sendai-shi Miyagi 980-8577 / JP
03 / ASANO, Ryutaro
c/o TOHOKU UNIVERSITY
1-1 Katahira 2-chome
Aoba-ku
Sendai-shi Miyagi 980-8577 / JP
04 / UMETSU, Mitsuo
c/o TOHOKU UNIVERSITY
1-1 Katahira 2-chome
Aoba-ku
Sendai-shi Miyagi 980-8577 / JP
 [2012/39]
Representative(s)Woods, Geoffrey Corlett
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
[2012/39]
Application number, filing date10831507.811.11.2010
[2016/01]
WO2010JP70127
Priority number, dateJP2009026314718.11.2009         Original published format: JP 2009263147
[2012/39]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011062112
Date:26.05.2011
Language:JA
[2011/21]
Type: A1 Application with search report 
No.:EP2502936
Date:26.09.2012
Language:EN
[2012/39]
Type: B1 Patent specification 
No.:EP2502936
Date:06.01.2016
Language:EN
[2016/01]
Search report(s)International search report - published on:JP26.05.2011
(Supplementary) European search report - dispatched on:EP03.12.2012
ClassificationIPC:A61K39/00, A61P35/00, C07K16/22, C07K16/28, C07K16/46
[2015/21]
CPC:
C07K16/2809 (EP,US); C07K16/22 (US); A61P35/00 (EP);
C07K16/2863 (EP,US); C07K2317/24 (EP,US); C07K2317/31 (EP,US);
C07K2317/565 (EP,US); C07K2317/567 (EP,US); C07K2317/622 (EP,US);
C07K2317/626 (EP,US); C07K2317/73 (EP,US); C07K2317/92 (EP,US) (-)
Former IPC [2012/39]C07K16/28, A61K39/395, A61P35/00, C07K16/46, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12N15/09, C12P21/08
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/39]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:HOCHFUNKTIONELLER MUTANT VARIABLER REGIONEN DES HUMANEN ANTI-EGFR-ANTIKÖRPERS[2012/39]
English:HIGHLY-FUNCTIONAL MUTANT OF HUMANIZED ANTI-EGFR ANTIBODY VARIABLE REGION[2012/39]
French:MUTANT HAUTEMENT FONCTIONNEL DE RÉGION VARIABLE D'ANTICORPS ANTI-EGFR HUMANISÉE[2012/39]
Entry into regional phase18.06.2012Translation filed 
18.06.2012National basic fee paid 
18.06.2012Search fee paid 
18.06.2012Designation fee(s) paid 
18.06.2012Examination fee paid 
Examination procedure18.06.2012Examination requested  [2012/39]
21.06.2013Amendment by applicant (claims and/or description)
03.09.2013Despatch of a communication from the examining division (Time limit: M06)
30.01.2014Reply to a communication from the examining division
14.02.2014Despatch of a communication from the examining division (Time limit: M06)
22.08.2014Reply to a communication from the examining division
10.04.2015Cancellation of oral proceeding that was planned for 16.04.2015
16.04.2015Date of oral proceedings (cancelled)
29.06.2015Communication of intention to grant the patent
28.10.2015Fee for grant paid
28.10.2015Fee for publishing/printing paid
28.10.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.09.2013
Opposition(s)07.10.2016No opposition filed within time limit [2016/50]
Fees paidRenewal fee
13.11.2012Renewal fee patent year 03
18.11.2013Renewal fee patent year 04
10.11.2014Renewal fee patent year 05
10.11.2015Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU11.11.2010
AL06.01.2016
AT06.01.2016
BE06.01.2016
CY06.01.2016
CZ06.01.2016
DK06.01.2016
EE06.01.2016
ES06.01.2016
FI06.01.2016
HR06.01.2016
IT06.01.2016
LT06.01.2016
LV06.01.2016
MC06.01.2016
MK06.01.2016
NL06.01.2016
PL06.01.2016
RO06.01.2016
RS06.01.2016
SE06.01.2016
SI06.01.2016
SK06.01.2016
SM06.01.2016
TR06.01.2016
BG06.04.2016
NO06.04.2016
GR07.04.2016
IS06.05.2016
PT06.05.2016
[2018/46]
Former [2018/29]HU11.11.2010
AT06.01.2016
BE06.01.2016
CY06.01.2016
CZ06.01.2016
DK06.01.2016
EE06.01.2016
ES06.01.2016
FI06.01.2016
HR06.01.2016
IT06.01.2016
LT06.01.2016
LV06.01.2016
MC06.01.2016
MK06.01.2016
NL06.01.2016
PL06.01.2016
RO06.01.2016
RS06.01.2016
SE06.01.2016
SI06.01.2016
SK06.01.2016
SM06.01.2016
TR06.01.2016
BG06.04.2016
NO06.04.2016
GR07.04.2016
IS06.05.2016
PT06.05.2016
Former [2018/28]HU11.11.2010
AT06.01.2016
BE06.01.2016
CY06.01.2016
CZ06.01.2016
DK06.01.2016
EE06.01.2016
ES06.01.2016
FI06.01.2016
HR06.01.2016
IT06.01.2016
LT06.01.2016
LV06.01.2016
MC06.01.2016
MK06.01.2016
NL06.01.2016
PL06.01.2016
RO06.01.2016
RS06.01.2016
SE06.01.2016
SI06.01.2016
SK06.01.2016
SM06.01.2016
BG06.04.2016
NO06.04.2016
GR07.04.2016
IS06.05.2016
PT06.05.2016
Former [2017/15]AT06.01.2016
BE06.01.2016
CZ06.01.2016
DK06.01.2016
EE06.01.2016
ES06.01.2016
FI06.01.2016
HR06.01.2016
IT06.01.2016
LT06.01.2016
LV06.01.2016
NL06.01.2016
PL06.01.2016
RO06.01.2016
RS06.01.2016
SE06.01.2016
SI06.01.2016
SK06.01.2016
SM06.01.2016
BG06.04.2016
NO06.04.2016
GR07.04.2016
IS06.05.2016
PT06.05.2016
Former [2017/03]AT06.01.2016
BE06.01.2016
CZ06.01.2016
DK06.01.2016
EE06.01.2016
ES06.01.2016
FI06.01.2016
HR06.01.2016
IT06.01.2016
LT06.01.2016
LV06.01.2016
NL06.01.2016
PL06.01.2016
RO06.01.2016
RS06.01.2016
SE06.01.2016
SK06.01.2016
SM06.01.2016
NO06.04.2016
GR07.04.2016
IS06.05.2016
PT06.05.2016
Former [2016/50]AT06.01.2016
CZ06.01.2016
DK06.01.2016
EE06.01.2016
ES06.01.2016
FI06.01.2016
HR06.01.2016
IT06.01.2016
LT06.01.2016
LV06.01.2016
NL06.01.2016
PL06.01.2016
RO06.01.2016
RS06.01.2016
SE06.01.2016
SK06.01.2016
SM06.01.2016
NO06.04.2016
GR07.04.2016
IS06.05.2016
PT06.05.2016
Former [2016/49]AT06.01.2016
DK06.01.2016
EE06.01.2016
ES06.01.2016
FI06.01.2016
HR06.01.2016
IT06.01.2016
LT06.01.2016
LV06.01.2016
NL06.01.2016
PL06.01.2016
RS06.01.2016
SE06.01.2016
NO06.04.2016
GR07.04.2016
IS06.05.2016
PT06.05.2016
Former [2016/46]AT06.01.2016
DK06.01.2016
ES06.01.2016
FI06.01.2016
HR06.01.2016
IT06.01.2016
LT06.01.2016
LV06.01.2016
NL06.01.2016
PL06.01.2016
RS06.01.2016
SE06.01.2016
NO06.04.2016
GR07.04.2016
IS06.05.2016
PT06.05.2016
Former [2016/39]AT06.01.2016
ES06.01.2016
FI06.01.2016
HR06.01.2016
IT06.01.2016
LT06.01.2016
LV06.01.2016
NL06.01.2016
PL06.01.2016
RS06.01.2016
SE06.01.2016
NO06.04.2016
GR07.04.2016
IS06.05.2016
PT06.05.2016
Former [2016/38]AT06.01.2016
ES06.01.2016
FI06.01.2016
HR06.01.2016
IT06.01.2016
LT06.01.2016
NL06.01.2016
PL06.01.2016
NO06.04.2016
GR07.04.2016
IS06.05.2016
PT06.05.2016
Former [2016/36]AT06.01.2016
ES06.01.2016
FI06.01.2016
HR06.01.2016
IT06.01.2016
LT06.01.2016
NL06.01.2016
PL06.01.2016
NO06.04.2016
GR07.04.2016
Former [2016/35]ES06.01.2016
FI06.01.2016
HR06.01.2016
NL06.01.2016
NO06.04.2016
GR07.04.2016
Former [2016/30]NL06.01.2016
Documents cited:Search[I]EP2006379  (UNIV TOHOKU [JP]) [I] 1-15 * figure 3; examples 1-11; sequences 25-28 *;
 [I]  - R. ASANO ET AL, "Highly Effective Recombinant Format of a Humanized IgG-like Bispecific Antibody for Cancer Immunotherapy with Retargeting of Lymphocytes to Tumor Cells", JOURNAL OF BIOLOGICAL CHEMISTRY, (20070101), vol. 282, no. 38, doi:10.1074/jbc.M704719200, ISSN 0021-9258, pages 27659 - 27665, XP055043823 [I] 1-15 * figures 1-15 *

DOI:   http://dx.doi.org/10.1074/jbc.M704719200
 [T]  - T. NAKANISHI ET AL, "Development of an affinity-matured humanized anti-epidermal growth factor receptor antibody for cancer immunotherapy", PROTEIN ENGINEERING DESIGN AND SELECTION, (20121001), doi:10.1093/protein/gzs088, ISSN 1741-0126, XP055043817 [T] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1093/protein/gzs088
International search[A]WO0206486  (TOHOKU TECHNO ARCH CO LTD [JP], et al);
 [X]JP2004242638  (TOHOKU TECHNO ARCH CO LTD);
 [Y]WO2007108152  (UNIV TOHOKU [JP], et al);
 [AP]JP2010119303  (UNIV TOHOKU);
 [AP]WO2010109924  (UNIV TOHOKU [JP], et al);
 [Y]  - URPO LAMMINMAKI ET AL., "Expanding the Conformational Diversity by Random Insertions to CDRH2 Results in Improved Anti-estradiol Antibodies", J. MOL. BIOL., (1999), vol. 291, pages 589 - 602, XP008159026

DOI:   http://dx.doi.org/10.1006/jmbi.1999.2981
 [Y]  - KARINE MERIENNE ET AL., "The Functional Architecture of an Acetylcholine Receptor- mimicking Antibody", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (1997), vol. 272, no. 38, pages 23775 - 23783, XP008159029

DOI:   http://dx.doi.org/10.1074/jbc.272.38.23775
 [Y]  - KOHEI TSUMOTO ET AL., "Thermodynamic and kinetic analyses of the antigen-antibody interaction using mutants", THE JAPANESE SOCIETY FOR ARTIFICIAL INTELLIGENCE CHISHIKI BASE SYSTEM KENKYUKAI SHIRYO, (2000), vol. 49, pages 83 - 88, XP008160325
 [Y]  - ALEXANDER A. KORTT ET AL., "Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting", BIOMOLECULAR ENGINEERING, (2001), vol. 18, pages 95 - 108, XP008159040

DOI:   http://dx.doi.org/10.1016/S1389-0344(01)00090-9
by applicantJPH0380790
 WO9222653
 EP0239400
 EP0451216
 JP3803790B
 WO2007108152
    - SCIENCE, (20080815), vol. 321, no. 5891, pages 974 - 7
    - E. COLI, J MOL BIOL, (2003), vol. 330, no. 1, pages 99 - 111
    - The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315
    - HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - ALT M, "Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gammal Fc or CH3 region", FEBS LETT., (1999), vol. 454, pages 90 - 4
    - LU D, "A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity", J BIOL CHEM., (2005), vol. 280, doi:doi:10.1074/JBC.M500815200, pages 19665 - 72, XP002516978

DOI:   http://dx.doi.org/10.1074/JBC.M500815200
    - BIOMOL. ENG., (2001), vol. 18, no. 3, pages 95 - 108
    - BIOCHEM BIOPHYSIC RES COMMUN., (2004), vol. 315, no. 4, pages 912 - 8
    - J IMMUNOL METHODS, (1997), vol. 201, pages 35 - 55
    - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
    - REICHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329
    - PRESTA, CURR. OP. STRUCT. BIOL, (1992), vol. 2, pages 593 - 596
    - ADAIR, J. R. ET AL., "Humanization of the murine anti-human CD3 monoclonal antibody OKT3", HUM ANTIBODIES HYBRIDOMAS, (1994), vol. 5, pages 41 - 7, XP009065026
    - CARILLO, H.; LIPMAN, D., SIAM J. APPLIED MATH., (1988), vol. 48, page 1073
    - DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, (1984), vol. 12, no. 1, page 387
    - ATSCHUL, S. F. ET AL., J. MOLEC. BIOL., (1990), vol. 403, page 215
    - R. SAIKI ET AL., SCIENCE, (1985), vol. 230, page 1350
    - R. SAIKI ET AL., SCIENCE, (1988), vol. 239, page 487
    - DNA Cloning, IRL PRESS, OXFORD UNIVERSITY PRESS, (1995), vol. 1
    - M.A. FROHMAN, PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 8998 - 9002
    - SANGER ET AL., PROC. NATL. ACAD. SCI. USA, (1977), vol. 74, pages 5463 - 5467
    - D.M. GLOVER ET AL., The Practical Approach Series, IRL PRESS, OXFORD UNIVERSITY PRESS, (1995), vol. 1-4
    - D. M. GLOVER ET AL., DNA Cloning, IRL PRESS, OXFORD UNIVERSITY PRESS, (1995), vol. 1-4
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.